Newsfeeds - Spark Newswire

2 minute read

FDA
News

Genmab And AbbVie Announce Topline Results For Epcoritamab From Phase 1/2 Trial In Patients With Relapsed/Refractory Large B-Cell Lymphoma

Today, 10:36 AM

Genmab A/S (NASDAQ:GMAB) and AbbVie (NYSE:ABBV) announced today topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2, clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an

ABBV

1 minute read

Morgan Stanley Maintains Underweight on Genmab, Lowers Price Target to $30

By Benzinga Newsdesk

Today, 10:36 AM

Morgan Stanley maintains Genmab (NASDAQ:GMAB) with a Underweight and lowers the price target from $33 to $30.

GMAB

1 minute read

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties

By Vandana Singh

Today, 10:36 AM

Johnson & Johnson’s (NYSE:JNJ) Janssen has won an arbitration against Genmab A/S (NASDAQ:GMAB) on two matters related to their licensing pact for…

GMAB

2 minute read

Legal
News

Genmab Announced the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement

By Charles Gross

Today, 10:36 AM

Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab. The arbitral tribunal issued an award on April 7, 2022, deciding both issues in favor of Janssen.

GMAB

2 minute read

Genmab Announces FDA Granted Orphan-Drug Designation To Epcoritamab In Follicular Lymphoma

By Benzinga Newsdesk

Today, 10:36 AM

Orphan drug status is designated by the FDA to medicines and biologics that are defined as those intended for the prevention, diagnosis, or treatment of a rare disease or condition affecting less than 200,000 people in

GMAB

1 minute read

HC Wainwright & Co. Upgrades Genmab to Buy, Announces $47 Price Target

By Benzinga Newsdesk

Today, 10:36 AM

HC Wainwright & Co. analyst Raghuram Selvaraju upgrades Genmab (NASDAQ:GMAB) from Neutral to Buy and announces $47 price target.

GMAB

2 minute read

News

Genmab And Synaffix Enter Into License Agreement For ADC Technology

By Bill Haddad

Today, 10:36 AM

COPENHAGEN, Denmark and AMSTERDAM, Jan. 4, 2022 /PRNewswire/ -- Genmab A/S (NASDAQ:GMAB) and Synaffix B.V., announced today that Genmab and Synaffix have signed a license agreement providing

GMAB

1 minute read

Guggenheim Downgrades Genmab to Neutral

By Benzinga Newsdesk

Today, 10:36 AM

Guggenheim analyst Michael Schmidt downgrades Genmab (NASDAQ:GMAB) from Buy to Neutral.

GMAB

1 minute read

A Bearish Sign Looms Over Genmab’s Chart

By Benzinga Insights

Today, 10:36 AM

If history is any guide, there may be trouble ahead for shares of Genmab (NASDAQ:GMAB). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

GMAB

1 minute read

Genmab Announced Janssen has Received Conditional European Marketing Authorization for RYBREVANT(amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-base

By Charles Gross

Today, 10:36 AM

Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted Conditional Marketing Authorization for Janssen's RYBREVANT® (amivantamab), a fully human bispecific antibody, for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor

GMAB